Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 75 years old (male or female)
- People whose liver cancer has been identified through pre-surgery scans as an early to intermediate stage (BCLC stage 0, A, or B) and is considered suitable for surgery to remove the cancer completely
- People with a good general health and activity level, as measured by a standard medical scoring system (ECOG score of 0–1) (confirm with trial site)
- People whose liver is functioning well, as measured by a standard liver health scoring system (Child-Pugh score of 5–6, also called Grade A) (confirm with trial site)
- People who have not yet received any cancer treatment
- People whose recent blood test results (taken within 7 days before joining) are within normal ranges
Who may not be able to join:
- People who are unable to provide a blood sample for a specialised DNA test (ctDNA testing)
- People who have two or more different types of cancer at the same time
- People whose liver tumour did not originally start in the liver (i.e., the cancer spread from somewhere else)
- Women who are pregnant or currently breastfeeding
- People who have had another type of cancer in the past 5 years or currently have another cancer alongside their liver cancer — with the exception of certain fully treated cancers including a specific type of skin cancer (basal cell carcinoma), early-stage cervical cancer (cervical carcinoma in situ), or a specific type of thyroid cancer (papillary thyroid carcinoma)
- People with serious heart disease
- People whom the research team considers unsuitable for the trial for other medical reasons (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mingxin Pan, Southern Medical University, China
Phone: +8618928918216
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2-year recurrence-free survival rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.